Clinical Trial: A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult Patients With Moderate to Severe Hidradenitis Suppurativa

U.S., Jan. 30 -- ClinicalTrials.gov registry received information related to the study (NCT06799000) titled 'A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult Patients With Moderate to Severe Hidradenitis Suppurativa' on Jan. 23.

Brief Summary: The purpose of this study is to establish the efficacy, safety, and tolerability of remibrutinib (LOU064) Dose A and Dose B compared to placebo in participants with moderate to severe hidradenitis suppurativa (HS).

Study Start Date: March 12

Study Type: INTERVENTIONAL

Condition: Hidradenitis Suppurativa

Intervention: DRUG: Remibrutinib Dose A

Remibrutinib Dose A (oral)

DRUG: Remibrutinib Dose B

Remibrutinib Dose B (oral)

DRUG: Placebo 1

Placebo matching t...